Drug intelligence / Profile preview

NeoCyte

Development stage: Unknown
Lead developer: IMAC Holdings
Modality: Cell Therapies
Administration: Subcutaneous, Intravenous, Intraperitoneal, Oral

Overview

NeoCyte is an umbilical cord-derived mononuclear cell product developed and commercialized by BioFirma. It is classified as a regenerative biologic and is intended for use in IMAC Holdings' clinics. IMAC Holdings initially acquired a majority stake in BioFirma to secure a supply of NeoCyte for its operations and later divested BioFirma while retaining long-term discounted access to the product.

Brand names: NeoCyte

Targets

CSF3R (Granulocyte colony-stimulating factor receptor)

Beyond the preview

Go deeper on NeoCyte.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeoCyte.

Explore the full profile